The PDUFA extension adds regulatory uncertainty but the EU positive opinion and pending ASCO data provide a potential catalyst on June 2, 2026. Traders should watch for the ASCO presentation and any subsequent FDA communication; the stock may remain range-bound until a new PDUFA date is announced.
AZN drugs
AZN drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 27 $185.62entry
- T+1 · 6mo ago −0.15%α −0.70% · $185.34
- T+5 · 6mo ago −5.13%α −5.60% · $176.10
- T+20 · 5mo ago −1.40%α +0.90% · $183.02
- T+60 · 3mo ago −11.39%α −13.01% · $164.48
Price Chart
How similar events traded
Executive Summary
AstraZeneca announced the FDA extended the PDUFA date for camizestrant in HR+/HER2- advanced breast cancer to review additional data, including ctDNA clearance analyses to be presented at ASCO 2026. The FDA's advisory committee had previously failed to reach a majority vote in favor in April 2026, adding uncertainty; however, the EU's CHMP adopted a positive opinion on May 22, 2026, partially offsetting the delay. The extension introduces delay risk but is not a rejection, and the stock's historical negative drift on prior regulatory updates warrants a cautious view.
Key Facts
- FDA extended PDUFA date for camizestrant NDA (SERENA-6) to review additional data, including ctDNA clearance outcomes
- FDA's ODAC did not reach a majority vote in favor of the treatment strategy in April 2026
- EU's CHMP adopted a positive opinion recommending approval on May 22, 2026
- Camizestrant already approved in UAE and Saudi Arabia; regulatory reviews ongoing in Japan and other countries
- ctDNA clearance data linked to longer-term efficacy will be presented at ASCO 2026 on June 2, 2026
- Original PDUFA date was not disclosed; new date not specified
Financial Impact
Camizestrant targets a US addressable population of ~37,000 patients annually in 1st-line HR+/HER2- metastatic breast cancer with ESR1 mutations. Launch delay could affect peak sales estimates, though no specific revenue figures were provided.
Risk Factors
- Extended review raises risk of Complete Response Letter (CRL) if additional data do not satisfy FDA concerns
- FDA's April ODAC split vote signals unresolved efficacy/benefit questions
- Competitive landscape (oral SERDs from Roche, Sanofi, etc.) continues to evolve during delay
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-005381 |
| Document: 0001654954-26-005381-index-headers.html | 0001654954-26-005381 |
| Document: 0001654954-26-005381-index.html | 0001654954-26-005381 |
| Document: 0001654954-26-005381.txt | 0001654954-26-005381 |
Track record
77 reports on AZN
19 of 38 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 38 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
- Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
- Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
- Nov 4, 202611d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
- Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
- Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers